Clinical Trial Update: Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of M7824 (immune checkpoint inhibitor) and M9241 (immunocytokine) with SBRT in adults with advanced pancreatic cancer; study terminated with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Neoplasms

Drugs mentioned

• M7824 (bintrafusp alfa)
• M9241 (nexus immunocytokine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Histologically or Cytologically Confirmed Pancreatic Cancer, Unresectable or Borderline Resectable Pancreatic Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-05-18